Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease ...

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months of treatment, representing what B. Riley Securities called a “paradigm shift ...

Swiss drugmaker Roche reported better than expected first-half operating profit on Thursday, driven by strong sales of breast ...

In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...

The drugmaker’s sales were up 7% at constant currency from the same period last year.

(Reuters) -Swiss drugmaker Roche Holding plans to test whether an experimental medicine can prevent Alzheimer's disease ...

Roche Holding AG plans to test whether an experimental medicine can prevent Alzheimer’s disease symptoms in high-risk people, ...